Cargando…

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer

Despite the recent emergence of immune checkpoint inhibitors, clinical outcomes of metastatic NSCLC patients remain poor, pointing out the unmet need to develop novel therapies to enhance the anti-tumor immune response in NSCLC. In this regard, aberrant expression of the immune checkpoint molecule C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flieswasser, Tal, Van den Eynde, Astrid, Freire Boullosa, Laurie, Melis, Jöran, Hermans, Christophe, Merlin, Céline, Lau, Ho Wa, Van Audenaerde, Jonas, Lardon, Filip, Smits, Evelien, Pauwels, Patrick, Jacobs, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038060/ https://www.ncbi.nlm.nih.gov/pubmed/36970072 http://dx.doi.org/10.1080/2162402X.2023.2192100

Ejemplares similares

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
por: Van Loenhout, Jinthe, et al.
Publicado: (2021)

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
por: Freire Boullosa, Laurie, et al.
Publicado: (2022)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
por: Flieswasser, Tal, et al.
Publicado: (2019)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

Site-specific (68)Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
por: Dewulf, Jonatan, et al.
Publicado: (2023)

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
por: Freire Boullosa, Laurie, et al.
Publicado: (2021)

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
por: Deben, Christophe, et al.
Publicado: (2021)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells
por: Van Audenaerde, Jonas R.M., et al.
Publicado: (2017)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
por: Deben, Christophe, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
por: Domen, Andreas, et al.
Publicado: (2021)

Cellular senescence in cancer: clinical detection and prognostic implications
por: Domen, Andreas, et al.
Publicado: (2022)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

The effect of local non‐thermal plasma therapy on the cancer‐immunity cycle in a melanoma mouse model
por: Lin, Abraham, et al.
Publicado: (2022)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
por: Jordaens, Stephanie, et al.
Publicado: (2020)

Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients
por: Berghmans, Eline, et al.
Publicado: (2020)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
por: Verhoeven, Yannick, et al.
Publicado: (2021)

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
por: De Waele, Jorrit, et al.
Publicado: (2021)

Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
por: Baay, Marc, et al.
Publicado: (2011)

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia
por: Boullosa, Laurie Freire, et al.
Publicado: (2017)

OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
por: Deben, Christophe, et al.
Publicado: (2022)

RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
por: van Dam, Peter A., et al.
Publicado: (2019)

Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays
por: Limame, Ridha, et al.
Publicado: (2012)

MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients
por: Deben, Christophe, et al.
Publicado: (2017)

Krüppel-like factors in cancer progression: three fingers on the steering wheel
por: Limame, Ridha, et al.
Publicado: (2013)

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s4eqeb2nvcrnk8nnqvb6b1i2eo